Nyxoah (NYXH) - Total Liabilities
Based on the latest financial reports, Nyxoah (NYXH) has total liabilities worth €42.65 Million EUR (≈ $49.86 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Nyxoah (NYXH) net asset momentum to track the company's year-over-year net asset growth rate.
Nyxoah - Total Liabilities Trend (2017–2024)
This chart illustrates how Nyxoah's total liabilities have evolved over time, based on quarterly financial data.
Nyxoah Competitors by Total Liabilities
The table below lists competitors of Nyxoah ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lion Finance Group PLC
LSE:BGEO
|
UK | GBX50.23 Billion |
|
Wspierania Przedsiebiorczosci
WAR:PTW
|
Poland | zł87.38 Million |
|
Oriental Food Industries Hold
KLSE:7107
|
Malaysia | RM78.50 Million |
|
Aksu Enerji ve Ticaret AS
IS:AKSUE
|
Turkey | TL280.17 Million |
|
Awanbiru Technology Bhd
KLSE:5204
|
Malaysia | RM77.09 Million |
|
Paradigm Biopharmaceuticals Ltd
AU:PAR
|
Australia | AU$17.16 Million |
|
Commercial Vehicle Group Inc
NASDAQ:CVGI
|
USA | $263.74 Million |
|
Spruce Ridge Resources Ltd.
V:SHL
|
Canada | CA$449.73K |
Liability Composition Analysis (2017–2024)
This chart breaks down Nyxoah's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Nyxoah worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nyxoah's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nyxoah (2017–2024)
The table below shows the annual total liabilities of Nyxoah from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €45.15 Million ≈ $52.79 Million |
+72.76% |
| 2023-12-31 | €26.14 Million ≈ $30.55 Million |
+1.51% |
| 2022-12-31 | €25.75 Million ≈ $30.10 Million |
+15.94% |
| 2021-12-31 | €22.21 Million ≈ $25.96 Million |
+31.49% |
| 2020-12-31 | €16.89 Million ≈ $19.75 Million |
+47.10% |
| 2019-12-31 | €11.48 Million ≈ $13.42 Million |
+52.58% |
| 2018-12-31 | €7.53 Million ≈ $8.80 Million |
+13.71% |
| 2017-12-31 | €6.62 Million ≈ $7.74 Million |
-- |
About Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgi… Read more